Understanding the Investigation into uniQure N.V.
In a recent development, Bragar Eagel & Squire, P.C., a law firm recognized nationally for its stockholder rights advocacy, has launched an investigation into uniQure N.V. (NASDAQ: QURE). The firm aims to determine whether uniQure has potentially violated federal securities laws or engaged in other unlawful business practices that may have adversely impacted its shareholders.
What Prompted the Investigation?
The investigation comes in light of a press release issued by uniQure, where it was disclosed that the Food and Drug Administration (FDA) no longer views data from the Phase I/II studies of AMT-130 as adequate compared to an external control, raising concerns over the timeline for submitting a Biologics License Application (BLA). Following this alarming news, uniQure's shares experienced a significant drop, falling over 57% in early trading, a serious blow to its stockholders.
Steps for Affected Shareholders
This situation raises several concerns for investors who may have acquired shares in uniQure. If you are among those who purchased uniQure stock and are worried about their investments, it’s crucial to understand your legal rights. Investors are encouraged to discuss their options with the firm’s representatives.
Contact Information for Support
Brandon Walker and Marion Passmore, partners at Bragar Eagel & Squire, are available for direct contact at (212) 355-4648. They are ready to assist investors dealing with losses as a result of the recent decline in stock value.
The Role of Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is dedicated to helping shareholders in navigating complex legal issues related to corporate governance and securities law. Their expertise lays the groundwork for a robust representation of individual and institutional investors facing potential losses.
What to Expect Next?
As the investigation unfolds, shareholders should remain informed about developments surrounding uniQure. The firm advises being proactive—if you have any information regarding this situation or have questions about your rights, reach out to them directly.
About uniQure N.V.
uniQure N.V. is known for its pioneering approaches to gene therapies. The company is focused on treating severe genetic diseases, leveraging advanced technologies. Its innovative pipeline includes promising programs aimed at addressing critical health issues.
Keeping Updated with Legal Actions
All stakeholders should continue to monitor the situation closely. Classes of stockholder claims can emerge from significant incidents like this, and having a legal firm like Bragar Eagel & Squire, P.C. engaged can make a difference in potentially recovering losses.
Frequently Asked Questions
What prompted the investigation into uniQure N.V.?
The investigation was initiated due to revelations from an FDA press release indicating that development data for AMT-130 may not support an adequate submission for a Biologics License Application.
Who can I contact if I have lost money investing in uniQure?
Investors concerned about their losses should contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire, P.C. by calling (212) 355-4648 for assistance.
What are the potential legal implications for uniQure shareholders?
Shareholders may have claims related to securities law violations if they suffered financial losses linked to misleading information or inadequate disclosures from the company.
How can I get updates regarding this situation?
Staying in touch with Bragar Eagel & Squire, P.C. is advisable for ongoing updates. They will play a significant role in any legal actions and share developments with shareholders.
Is there any cost involved in pursuing a claim against uniQure?
No, reaching out for guidance from Bragar Eagel & Squire incurs no cost. They offer initial consultations to evaluate your situation without any obligation to proceed.
